KZR
Price
$4.50
Change
-$0.10 (-2.17%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
32.88M
SAGE
Price
$7.37
Change
-$0.40 (-5.15%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
453.11M
33 days until earnings call
Ad is loading...

KZR vs SAGE

Header iconKZR vs SAGE Comparison
Open Charts KZR vs SAGEBanner chart's image
Kezar Life Sciences
Price$4.50
Change-$0.10 (-2.17%)
Volume$447
Capitalization32.88M
Sage Therapeutics
Price$7.37
Change-$0.40 (-5.15%)
Volume$15.1K
Capitalization453.11M
KZR vs SAGE Comparison Chart
Loading...
KZR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KZR vs. SAGE commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KZR is a Hold and SAGE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (KZR: $4.60 vs. SAGE: $7.77)
Brand notoriety: KZR and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KZR: 31% vs. SAGE: 56%
Market capitalization -- KZR: $32.88M vs. SAGE: $453.11M
KZR [@Biotechnology] is valued at $32.88M. SAGE’s [@Biotechnology] market capitalization is $453.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KZR’s FA Score shows that 1 FA rating(s) are green whileSAGE’s FA Score has 0 green FA rating(s).

  • KZR’s FA Score: 1 green, 4 red.
  • SAGE’s FA Score: 0 green, 5 red.
According to our system of comparison, SAGE is a better buy in the long-term than KZR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KZR’s TA Score shows that 4 TA indicator(s) are bullish while SAGE’s TA Score has 2 bullish TA indicator(s).

  • KZR’s TA Score: 4 bullish, 5 bearish.
  • SAGE’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, KZR is a better buy in the short-term than SAGE.

Price Growth

KZR (@Biotechnology) experienced а -11.03% price change this week, while SAGE (@Biotechnology) price change was -9.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

KZR is expected to report earnings on Mar 13, 2025.

SAGE is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAGE($453M) has a higher market cap than KZR($32.9M). SAGE YTD gains are higher at: 43.094 vs. KZR (-31.548). KZR has higher annual earnings (EBITDA): -93.11M vs. SAGE (-409.48M). SAGE has more cash in the bank: 504M vs. KZR (148M). SAGE has less debt than KZR: SAGE (11.8M) vs KZR (16.9M). SAGE has higher revenues than KZR: SAGE (41.2M) vs KZR (0).
KZRSAGEKZR / SAGE
Capitalization32.9M453M7%
EBITDA-93.11M-409.48M23%
Gain YTD-31.54843.094-73%
P/E RatioN/AN/A-
Revenue041.2M-
Total Cash148M504M29%
Total Debt16.9M11.8M143%
FUNDAMENTALS RATINGS
KZR vs SAGE: Fundamental Ratings
KZR
SAGE
OUTLOOK RATING
1..100
6123
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
9143
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KZR's Valuation (14) in the Biotechnology industry is in the same range as SAGE (36) in the Pharmaceuticals Other industry. This means that KZR’s stock grew similarly to SAGE’s over the last 12 months.

KZR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SAGE (100) in the Pharmaceuticals Other industry. This means that KZR’s stock grew similarly to SAGE’s over the last 12 months.

KZR's SMR Rating (97) in the Biotechnology industry is in the same range as SAGE (98) in the Pharmaceuticals Other industry. This means that KZR’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's Price Growth Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for KZR (91) in the Biotechnology industry. This means that SAGE’s stock grew somewhat faster than KZR’s over the last 12 months.

SAGE's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as KZR (100) in the Biotechnology industry. This means that SAGE’s stock grew similarly to KZR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KZRSAGE
RSI
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
73%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
KZR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SPIR8.100.16
+2.02%
Spire Global
KIRK1.310.02
+1.55%
Kirkland's
AMP494.365.68
+1.16%
Ameriprise Financial
STBA37.330.18
+0.48%
S&T Bancorp
AGO87.70-0.40
-0.45%
Assured Guaranty Ltd